mHealth Mood Management Tool (Actify) to Improve Population-Level Smoking Cessation
NCT ID: NCT04525222
Last Updated: 2024-03-07
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
242 participants
INTERVENTIONAL
2022-05-09
2023-04-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of An Innovative Smartphone Intervention for Smoking Cessation
NCT02724462
Identifying Treatments to Motivate Smokers to Quit
NCT01122238
Smartphone-delivered Scheduled Smoking With Compliance Facilitation as an Adjunct Cessation Therapy: a Feasibility Study
NCT05763771
Use of a Smartphone Mobile Application (App) to Enhance Smoking Cessation Treatment
NCT03519451
Smartphone-Delivered Attentional Bias Modification Training in Helping Patients Quit Smoking
NCT02224391
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ARM I: Participants use Actify app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text notifications.
ARM II: Participants use United States (US) Clinical Practice Guidelines (USCPG) app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text notifications.
After completion of study, participants are followed up at 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (Actify, text notifications)
Participants use Actify app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text notifications.
Health Promotion and Education
Receive motivational messages and smoking cessation information via text notifications
Smoking Cessation Intervention (Actify app)
Use Actify app
Survey Administration
Ancillary studies
Arm II (Current Standard Care, text notifications)
Participants use app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text notifications.
Health Promotion and Education
Receive motivational messages and smoking cessation information via text notifications
Smoking Cessation Intervention (Current Standard Care app)
Use (USCPG) Current Standard Care app
Survey Administration
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Health Promotion and Education
Receive motivational messages and smoking cessation information via text notifications
Smoking Cessation Intervention (Actify app)
Use Actify app
Smoking Cessation Intervention (Current Standard Care app)
Use (USCPG) Current Standard Care app
Survey Administration
Ancillary studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Interested in quitting smoking in the next 30 days
* Experience downloading and using one or more apps on their smartphone
* Either screens negative (Patient Health Questionnaire - 9 Item \[PHQ-9\] score 0-4) for depression or screens positive for mild to moderate current depressive symptoms (PHQ-9 score 5-19)
* Willing and able to complete all study activities
* Comfortable reading and writing in English
* Have a mobile data plan and/or access to WiFi to support the use of the Actify app
* Reside in the US
* Have a smartphone either an iPhone (running iOS version 11 or higher) or an Android phone (running version 5.0 or higher)
Exclusion Criteria
* Current use of a depression app
* Severe depression (PHQ-9 \>= 20)
* Receiving other treatment for smoking cessation
* Previous use of the QuitGuide app
* Current or recent (within the past year) enrollment in a Fred Hutch smoking cessation study
* Employees/family of investigator or study center
* Member of the same household as another participant
* Woman who is pregnant or breastfeeding, or planning to become pregnant
* Currently incarcerated
* Is ineligible per fraud prevention protocol
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Fred Hutchinson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jaimee Heffner
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jaimee Heffner
Role: PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2020-05454
Identifier Type: REGISTRY
Identifier Source: secondary_id
10540
Identifier Type: OTHER
Identifier Source: secondary_id
RG1121054
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.